Showing results (11-20 of 79) with videos related to
Sort By:
Pageof 8
Best Practice & Research. Clinical Endocrinology & Metabolism|September 16, 2017
Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancerR Michael Tuttle, Marcia S Brose, Enrique Grande, et al.Cancer Letters|June 19, 2007
Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional responseRebekah K O'Donnell, Rosemarie Mick, Michael Feldman, et al.The American Journal of Managed Care|February 24, 2022
Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancerJosh J Carlson, Antoine Italiano, Marcia S Brose, et al.The American Journal of Managed Care|February 24, 2022
Diagnosis and management of TRK fusion cancerShivaani Kummar, Antoine Italiano, Marcia S Brose, et al.Cancer Treatment Reviews|April 29, 2018
Management of treatment-related toxicities in advanced medullary thyroid cancerMarcia S Brose, Keith C Bible, Laura Q M Chow, et al.Endocrine Pathology|December 15, 2015
STK11 Mutation Identified in Thyroid CarcinomaShuanzeng Wei, Virginia A LiVolsi, Marcia S Brose, et al.Journal of the National Cancer Institute|September 19, 2002
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation programMarcia S Brose, Timothy R Rebbeck, Kathleen A Calzone, et al.European Journal of Cancer (Oxford, England : 1990)|November 25, 2018
Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancerMakoto Tahara, Marcia S Brose, Lori J Wirth, et al.Molecular and Cellular Biology|May 5, 2010
Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesionOxana M Tsygankova, Changqing Ma, Waixing Tang, et al.Endocrine-Related Cancer|March 9, 2017
Timing of multikinase inhibitor initiation in differentiated thyroid cancerMarcia S Brose, Johannes Smit, Chia-Chi Lin, et al.Pageof 8